Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What to Expect From Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.
Allergan (AGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus
by Zacks Equity Research
Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.
AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
by Zacks Equity Research
AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.
Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca
by Zacks Equity Research
Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.
Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
by Zacks Equity Research
Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
by Zacks Equity Research
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
by Zacks Equity Research
Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
by Zacks Equity Research
Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
by Zacks Equity Research
AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.
Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.
Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.
What's in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.
What's in the Cards for Aerie (AERI) This Earnings Season?
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) is expected to throw light on updates on Rhopressa during its second-quarter earnings call on Aug 1.
Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) is likely to see continued momentum in Vimizim and Kuvan sales backed by robust patient growth in Q2.
What's in Store for Endocyte (ECYT) this Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
by Zacks Equity Research
Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.
Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion
by Zacks Equity Research
We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.
Healthcare ETF (IYH) Hits New 52-Week High
by Sweta Killa
This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?
Clovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3%
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS)) shares rose over 6% on solid volume after the company's announcement regarding the pricing of its shares
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.